Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a (BioGeneric Pharma)
- Development stage
- Approved
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
peginterferon alfa-2a (specifically the YPEG-IFNα-2a formulation) is a pegylated recombinant interferon alpha-2a developed by BioGeneric Pharma. It consists of the cytokine interferon alpha-2a conjugated to a unique Y-shaped polyethylene glycol (PEG) moiety, which is intended to enhance its pharmacokinetic profile, stability, and in vivo activity compared to traditional linear-PEG formulations. The drug exerts its effects by binding to the type I interferon receptor (IFNAR), a heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits. This binding activates the JAK-STAT signaling pathway, leading to the induction of various interferon-stimulated genes that provide antiviral, antiproliferative, and immunomodulatory responses. YPEG-IFNα-2a has been primarily investigated in clinical trials for the treatment of chronic hepatitis C virus (HCV) infection, often administered in combination with ribavirin, particularly in the Egyptian patient population.
- Brand names
- Reiferon Retard
- Other names
- Y-shaped pegylated interferon alpha-2apegylated interferon alpha 2a
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peginterferon alfa-2a (BioGeneric Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a (BioGeneric Pharma).